2019 Alzheimer’s disease and several other neurodegenerative diseases are associated with the accumulation in neurons of misfolded aggregation-prone proteins (e.g., tau and amyloid beta). Presently, no treatment is available to slow the steady accumulation of such toxic proteins. Such misfolded proteins in cells typically are selectively destroyed by the proteasome (the ...
April 28, 2016
Last week, US News & World Report recognized one of our Research Consortium’s leading scientists – Dr. David Holtzman. In the article, Holtzman was hailed as one of the top researchers in the field: “He’s clearly one of the leaders in Alzheimer’s disease research,” says Stephen Snyder, deputy director of ...
July 6, 2009
A new study adds another piece to the TREM2 puzzle by uncovering what happens when TREM2 levels are reduced in both a mouse model of Alzheimer’s disease and in post-mortem human brains. The findings published in Nature Neuroscience are from the laboratory of Dr. Christian Haass and his collaborators including ...
March 15, 2019
MIT scientists Manolis Kellis and Li-Huei Tsai are combining complex biological data with molecular biology to gain a new and unique understanding the brain. This research was published in NATURE and funded in part by Cure Alzheimer’s Fund. This desire to leave no stone-unturned in Alzheimer’s disease research led Dr. Tsai, ...
October 6, 2019
A new “alternative amyloid hypothesis” from the lab of Dr. Charles Glabe, at the University of California at Irvine, helps explain precisely how neurons (nerve cells) die in Alzheimer’s disease and how known genetic mutations initiate a chain reaction in this long process. The important new hypothesis was driven by ...
August 14, 2014
We fund research with the highest probability of slowing, stopping or reversing Alzheimer’s disease. Our approach consists of two principals: 1. The research we fund is based on a 4-part roadmap: (1) find all the genes that contribute to risk for the disease; (2) figure out which ones contribute the most and ...
August 21, 2009
Boston – Cure Alzheimer’s Fund recently awarded Dr. Nicholas Seeds, with the University of Colorado School of Medicine, a $100,000 grant for novel research on Alzheimer’s disease, which affects 5.2 million Americans and their families and is the most common cause of dementia in the elderly. “This research has the potential ...
May 12, 2010
Fresh off of summiting Aconcagua, the highest peak in South America, Alan Arnette is at it again. This spring, he will attempt to summit Everest—the highest peak on Earth at 29,035 feet. Everest is the third mountain in his 7 Summits Climb for Alzheimer’s: Memories are Everything campaign—his yearlong mission ...
April 15, 2011
Three recent discoveries by University of Southern California neuroscientist Berislav Zlokovic, M.D., Ph.D., have clarified one of the least-understood elements of Alzheimer’s disease: how the blood-brain barrier becomes compromised and contributes to the disease process. In healthy individuals, the blood-brain barrier (BBB) is a fine mesh filter that transports only select ...
July 22, 2015
Alzheimer’s disease (AD) remains the most common form of dementia, affecting 50 million people worldwide. Recent studies from our laboratory established a clear role for the gut microbiome in the pathology of AD. These studies also suggested rampant neuroinflammation in the AD brain, triggered by imbalances in gut-microbiome diversity. However, ...
December 15, 2020
